HSP90B2P and cancer: On the subject of lncRNAs, LIMIT (lncRNA inducing MHC-I and immunogenicity of tumor) disrupts the effects of HSP and leads to the subsequent transcription of the MHC-I machinery, so it is claimed to have a cancer immunogenic function (46).